Features | Partner Sites | Information | LinkXpress
Sign In
Bio-Rad Diabetes Division
RANDOX LABORATORIES
PURITAN MEDICAL

Rapid Diagnostic Tests Compared for Invasive Amoebiasis

By Labmedica International staff writers
Posted on 30 Oct 2013
Image: Bichrolatex-Amibe colored latex slide agglutination test for extra-intestinal amoebiasis serodiagnosis (Photo courtesy of Fumouze Diagnostic).
Image: Bichrolatex-Amibe colored latex slide agglutination test for extra-intestinal amoebiasis serodiagnosis (Photo courtesy of Fumouze Diagnostic).
Three rapid immunoassays have been compared and evaluated for the diagnosis of invasive amoebiasis in an emergency department.

Sensitive rapid diagnostic tests (RDT) contribute to an early diagnosis and thus improve the prognosis. The test should be also specific to distinguish amoebic and pyogenic abscess in order to avoid a percutaneous drainage for diagnostic purposes and a broad-spectrum antibiotherapy.

Scientists at the Military Teaching Hospital (HIA) Bégin (Saint-Mandé, France) carried out a retrospective biological records review that included 639 patients for whom three serological tests were performed. They compared a latex agglutination test (LAT) with enzyme-linked immunosorbent assay and indirect hemagglutination assay in the diagnosis of invasive amoebiasis (IA) performed from January 1, 2001, to July 1, 2012.

The three different techniques performed for each patient at laboratory of Bégin Hospital were: a latex agglutination slide test (LAT) (Bichrolatex-Amibe, Fumouze Diagnostic; Levallois-Perret, France); an enzyme linked immunosorbent assay (ELISA) (NovaTec Entamoeba histolytica IgG-ELISA, DiaSorin SPA; Saluggia, Italy); and the Fumouze Diagnostic’s indirect hemagglutination assay Amibiase HAI (IHA).

A total of 639 patients with a performed serology were included and among them 75 had at least one positive serological result. Of these 75 patients, 46 had a final diagnosis of IA, 43 with hepatic amoebiasis, two with intestinal amoebomas and one with pleuropulmonary amoebiasis and 29 patients had another final diagnosis. The LAT was statistically more sensitive than ELISA and IHA.

The authors concluded that LAT could be used in any routine clinical laboratory because it is simple to perform and does not require any special equipment. The result is achieved quickly in 15 minutes. The interpretation is easy because the bicolored positive pattern is very distinguishable from a negative brown spot. The cost remains low at approximately EUR 5.22 per test in France. The LAT is a useful screening technique in the rapid diagnosis and the management of patients with febrile hepatalgia in emergency units. However, this test should be systematically confirmed by reference techniques (ELISA, IHA). The study was published on October 11, 2013, in the journal Diagnostic Microbiology and Infectious Disease.

Related Links:

Military Teaching Hospital Bégin
Fumouze Diagnostic 
DiaSorin SPA 



KARL HECHT GMBH & CO KG
DIASYS DIAGNOSTIC SYSTEMS
ADVANCED INSTRUMENTS
WATERS CORPORATION

Channels

Genetic Tests

view channel

Overexpression of X Chromosome Genes Is Biomarker for Female Mental Disorders

A recent paper suggested that elevated expression of the genes XIST (X-inactive specific transcript) and KDM5C (lysine-specific demethylase 5C) could be used as a biological marker for diagnosis of major affective disorders in a significantly large subset of female patients from the general population. Xist is an RNA... Read more

Immunology

view channel

Powerful Innovations in Diagnostics Unveiled at EuroMedLab 2015

New systems presented by Roche include a new standard for immunology testing, an integrated platform for hematology diagnostics, and a high-throughput analyzer to perform HbA1c tests for blood glucose management. Also, evidence was presented for a high-sensitivity cardiac troponin test to provide earlier and more accurate... Read more

Industry News

view channel

Cloud-Based Systems Becoming Key Pillar in eHealth Strategy

Cloud-based laboratory information management systems (LIMS) are becoming a key pillar in Europe’s e-Health strategy as data-management solutions for modern testing will generate more demand for these systems. Investments in cloud-based LIMS are part of Europe’s e-Health strategy. New analysis from Frost & Sullivan... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.